Supplier News

The Luna Probe One-Step RT-qPCR Mix with UDG is designed to enable sensitive, linear, real-time detection of target RNA sequences.

Evonik has increased its global supply of plant-derived cholesterol used for mRNA vaccines and gene therapies.

Thermo Fisher and Symphogen have extended their collaboration involving improved data workflow, which supports the discovery and development of new cancer treatments.

Under a collaboration, IDT Biologika and Exothera will conduct feasibility studies on scaling up the manufacturing process for viral vector-based vaccines.

A new portfolio of chromatography and mass spectrometry consumables launched by Thermo Fisher Scientific is designed to meet higher performance requirements while remaining economical.

MilliporeSigma and Waters will work together to build an extractables and leachables (E&L) reference library.

Taconic Biosciences Cage+ colony management service aims to offer comprehensive coverage for contract breeding services.

Moderna and Thermo Fisher Scientific have formed a collaboration to leverage dedicated commercial fill/finish manufacturing capacity in the US for mRNA vaccines and therapies.

Semarion raises £2.14 million GBP (US$2.89 million) seed funding to support the commercial development of Semarion’s SemaCyte cell assaying platform.

Hoffman Neopac has signed a partnership with Saperatec to begin recycling aluminum laminate composites upon its opening in mid-2023.

Quotient Sciences announces that it has integrated drug substance into its flagship Translational Pharmaceutics platform.

Recipharm has strengthened its biologics manufacturing capabilities with the acquisition of both Vibalogics and Arranta Bio.

Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.

The deal between ProBioGen and AstraZeneca will allow AstraZeneca to use ProBioGen’s GlymaxX technology.

Thermo Fisher Scientific's solution for cell and gene therapies involves a combination of cold chain logistics, serialization compliance, and distribution

Piramal Pharma Solutions plans to construct a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth, Scotland, and to upgrades its existing API manufacturing facility in Morpeth, England.

Sartorius Stedim Biotech has completed the acquisition of the chromatography equipment division of Novasep.

The European Patent Office has granted another patent to Salipro Biotech, covering the composition-of-matter, methods, and uses of the company’s novel antigen technology.

Bio-Rad’s four new antibodies will develop highly selective and sensitive assays for bioanalysis and drug monitoring of pertuzumab and its biosimilars.

Gandeeva raisded $40 million to advance its AI-driven cryo-EM platform, with which it will develop new therapeutics based on the precise imaging of protein–drug interactions.

The acquisition will include Rewrite’s DNA writing platform, expanding Intellia’s genome editing tools.

Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.

Recipharm will build up its biologics service offering with the acquisition of GenIbet.

Metagenomi has successfully raised $175 million for use toward its research pipeline.

IonSense’s DART-MS technology offers rapid drug analysis without the need for sample preparation.

Gerresheimer is adding capacity in Germany, China, and the United States.

Texcell North America’s new lab facility in Frederick, Md., will expand the CRO’s capabilities in R&D cell culture, viral clearance studies, and viral safety testing.

Refeyn’s SamuxMP enables routine quantification of empty/full AAV capsid ratios, even in smaller labs, to set a new standard in AAV characterisation

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

Merck and Ridgeback Therapeutics will supply UNICEF with up to three million capsules of molnupiravir through the first half of 2022.